Why the study?
It remained unknown whether the elapsed time from stroke onset affects the relationship between CYP2C19 variants and recurrent cardiovascular events.
Do CYP2C19 variants affect the rate of composite cerebrocardiovascular events in non-acute stroke patients treated with clopidogrel?
Do CYP2C19 variants affect the rate of composite cerebrocardiovascular events in non-acute stroke patients treated with clopidogrel?
CYP2C19 variants do not significantly affect the rate of cerebrocardiovascular events in the chronic phase of stroke among patients treated with clopidogrel, despite affecting platelet reactivity.
Answers are grounded in this paper and cite their sources.
CYP2C19 variants may influence clopidogrel outcomes in chronic stroke; leaves open time-from-onset effects pending RCTs.
BACKGROUND: CYP2C19variants are associated with the antiplatelet effects of clopidogrel against recurrent cardiovascular events. However, it remains unknown whether the elapsed time from stroke onset affects the relationship between the genetic variants and such events. To address this, we conducted a prospective cohort study to determine the effect ofCYP2C19variants on clinical outcomes in the chronic phase. METHODS AND RESULTS: In total, 518 Japanese non-acute stroke patients treated with clopidogrel were registered at 14 institutions. Patients were classified into 3 clopidogrel-metabolizing groups according toCYP2C19genotype: extensive metabolizer (EM:*1/*1), intermediate metabolizer (IM:*1/*2or*1/*3), and poor metabolizer (PM:*2/*2,*2/*3, or*3/*3). Antiplatelet effects of clopidogrel were assessed by adenosine diphosphate (ADP)-induced platelet aggregation and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. The endpoint was composite cerebrocardiovascular events (CVEs). In 501 successfully followed-up patients, the median time from index stroke to enrollment was 181 days. There were 28 cardiovascular and 2 major bleeding events. There were no significant differences in the rates of cardiovascular events among the groups. CONCLUSIONS: Despite associations betweenCYP2C19variants and on-clopidogrel platelet reactivity, there was no significant difference in rates of CVEs in the chronic stroke phase among the 3 clopidogrel-metabolizing groups ofCYP2C19variants.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: